Allist(688578) 证券时报网·2025-04-23 14:48Company Overview - Ailis announced a 2024 annual distribution plan, proposing a cash dividend of 4 yuan per 10 shares (including tax), with a total expected cash payout of 180 million yuan, representing 12.59% of the net profit, marking the third cumulative cash distribution since the company's listing [2] - The company reported a revenue of 3.558 billion yuan for the year, a year-on-year increase of 76.29%, and a net profit of 1.430 billion yuan, up 121.97%, with a basic earnings per share of 3.18 yuan and a weighted average return on equity of 29.26% [2] Financial Performance - The company achieved a revenue of 3.558 billion yuan, reflecting a growth of 76.29% year-on-year [2] - The net profit reached 1.430 billion yuan, showing a significant increase of 121.97% compared to the previous year [2] - The basic earnings per share stood at 3.18 yuan, with a return on equity of 29.26% [2] Market Activity - The stock saw a net inflow of 8.8106 million yuan from main funds today, with a total net inflow of 10.8741 million yuan over the past five days [3] - The latest margin financing balance for the stock is 668 million yuan, with an increase of 19.2159 million yuan over the past five days, representing a growth of 2.96% [4] Industry Comparison - In the pharmaceutical and biotechnology sector, 186 companies have announced their 2024 distribution plans, with WuXi AppTec leading with a cash payout of 7.692 billion yuan, followed by Yunnan Baiyao and Hengrui Medicine with payouts of 2.114 billion yuan and 1.275 billion yuan, respectively [4]